Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.

Antimicrobial agents and chemotherapy - 1 May 1994

Fujii K, Tsuji A, Miyazaki S, Yamaguchi K, Goto S

Abstract excerpt

The in vitro and in vivo antibacterial activities of the new rifamycin derivatives KRM-1648 and KRM-1657 were compared with those of rifampin. Rifabutin, ciprofloxacin, and clarithromycin were also tested for reference. The respective MICs of KRM-1648 and KRM-1657 for 90% of the strains tested (MIC90S) were 0.016 and 0.0078 microgram/ml, respectively, for methicillin-susceptible Staphylococcus aureus, 0.016 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteria
Share to Drug Resistance, Microbial
Share to Mice

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Inbred ICR

Share to Mutation

Share to Rifampin

Share to Staphylococcal Infections

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 8067748
DOI: 10.1128/AAC.38.5.1118
PMCID: PMC188160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.PMID 8067748Read ↗

Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.Semantic proximity Read ↗

Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.Semantic proximity Read ↗

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.Semantic proximity Read ↗

Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.Semantic proximity Read ↗

Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.Semantic proximity Read ↗

In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Semantic proximity Read ↗

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Semantic proximity Read ↗

Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.Semantic proximity Read ↗

Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.Semantic proximity Read ↗

Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.Semantic proximity Read ↗

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative BacteriaSemantic proximity Read ↗

In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.